Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
INDAPTUS THERAPEUTICS INC (INDP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.16-4.24%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for INDP yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Stabilize senior management team to support execution | A supporting condition in INDAPTUS THERAPEUTICS INC's published investment case. The stated target is no further major senior executive departures in next 4 quarters. | Under Pressure | additional senior executive resignations occur | 1 director departure vs 0 senior exec departures Director Tim Ruan resigned in Sept 2026; no senior executive departures reported. $24M private placement completed. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making biotechnology business rather than an established earnings compounder. The long-term thesis is intact in the snapshot, but confidence is low and depends on strategic alternatives, research collaborations, and leadership transition.
The evidence does not provide a valuation measure or a clear account of market expectations, so whether INDP is cheap, fair, or expensive cannot be assessed. Recent price reaction is described as muted, but that alone does not show what the market assumes.
Near term, management is winding down Decoy20 enrollment, has no active clinical programs, and is evaluating alternatives while reducing expenses. A private placement lifted cash and short-term investments from the prior quarter, but the company remains loss-making and recently missed a quarter amid erratic earnings surprises, creating elevated next-quarter risk.
Over the multi-year view, the key swing factor is whether management finds a strategic path or research collaborations that can support the business after the clinical wind-down. Near term, weakening jobs data could weigh on cyclical names, while continued strength or weakness from healthcare bellwethers may reinforce or fade the sector tailwind.
INDP remains a low-confidence, high-risk strategic reassessment with improved liquidity but no active clinical programs and ongoing losses. The 1-to-3-year view hinges on credible strategic progress and continued financial support. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Manage net losses to avoid worsening financial health |
| Indaptus aims to manage cash flow despite net losses near -$8.11M in 2025-Q4. |
| Broken |
| net losses worsen beyond -$8.11M in any quarter |
Net income: $-1.795M FY2026-Q2; GAAP. Published target: net losses do not worsen beyond -$8.11M in next 4 quarters. Target period is not explicitly aligned with this observation. Aug 13, 2026-1,794,863 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stabilize cash from operations to sustain operations | Indaptus aims to manage cash flow despite net losses near -$8.11M in 2025-Q4. | Broken | cash from operations worsens beyond -$7.01M in any quarter | Cash from operations: $-1.928M FY2026-Q2; GAAP. Published target: cash from operations does not decline further beyond -$7.01M in next 4 quarters. Target period is not explicitly aligned with this observation. Aug 13, 2026-1,927,634 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.42 → $-4.42 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-4.42 | Unavailable | 1 / 0 |
| 2026-07-25 | $-4.42 | Unavailable | 1 / 0 |
| 2026-07-26 | $-4.42 | Unavailable | 1 / 0 |
| 2026-07-27 | $-4.42 | Unavailable | 1 / 0 |
| 2026-07-28 | $-4.42 | Unavailable | 1 / 0 |
| 2026-07-29 | $-4.48 | $0 | 1 / 1 |
| 2026-07-30 | $-4.48 | $0 | 1 / 1 |
| 2026-07-31 | $-4.48 | $0 | 1 / 1 |
| 2026-08-01 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-02 | $-4.48 | $0 | 1 / 1 |
| 2026-08-03 | $-4.48 | $0 | 1 / 1 |
| 2026-08-04 | $-4.48 | $0 | 1 / 1 |
| 2026-08-05 | $-4.48 | $0 | 1 / 1 |
| 2026-08-06 | $-4.48 | $0 | 1 / 1 |
| 2026-08-07 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-08 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-09 | $-4.48 | $0 | 1 / 1 |
| 2026-08-10 | $-4.48 | $0 | 1 / 1 |
| 2026-08-12 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-13 | $-4.48 | $0 | 1 / 1 |
| 2026-08-14 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-15 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-16 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-17 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-18 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-19 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-20 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-21 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-22 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-23 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-24 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-25 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-26 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-27 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-28 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-29 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-30 | $-4.42 | Unavailable | 1 / 0 |
| 2026-08-31 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-01 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-02 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-03 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-04 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-05 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-06 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-07 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-08 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-09 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-10 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-11 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-12 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-13 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-14 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-15 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-16 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-17 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-18 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-19 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-20 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-21 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-22 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-23 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-24 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-25 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-26 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-27 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-28 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-29 | $-4.42 | Unavailable | 1 / 0 |
| 2026-09-30 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-01 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-02 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-03 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-04 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-05 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-06 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-07 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-08 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-09 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-10 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-11 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-12 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-13 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-14 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-15 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-16 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-17 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-18 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-19 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-20 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-21 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-22 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-23 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-24 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-25 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-26 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-27 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-28 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-29 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-30 | $-4.42 | Unavailable | 1 / 0 |
| 2026-10-31 | $-4.42 | Unavailable | 1 / 0 |
| 2026-11-01 | $-4.42 | Unavailable | 1 / 0 |
| 2026-11-02 | $-4.42 | Unavailable | 1 / 0 |
| 2026-11-03 | $-4.42 | Unavailable | 1 / 0 |
| 2026-11-04 | $-4.42 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.